269 related articles for article (PubMed ID: 11246598)
1. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
Oelkers W
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
[TBL] [Abstract][Full Text] [Related]
2. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
Oelkers WH
Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
[TBL] [Abstract][Full Text] [Related]
3. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
Oelkers W
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
[TBL] [Abstract][Full Text] [Related]
4. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
5. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
[TBL] [Abstract][Full Text] [Related]
6. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
Foidart JM
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
[TBL] [Abstract][Full Text] [Related]
7. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of different progestogens: the special case of drospirenone.
Sitruk-Ware R
Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
[TBL] [Abstract][Full Text] [Related]
9. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
10. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
11. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
Oelkers W
Mol Cell Endocrinol; 2004 Mar; 217(1-2):255-61. PubMed ID: 15134826
[TBL] [Abstract][Full Text] [Related]
12. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
13. Yasmin--a new oral contraceptive, a new progestogen: the reasons why.
Mansour D
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601
[TBL] [Abstract][Full Text] [Related]
14. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
[TBL] [Abstract][Full Text] [Related]
15. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women.
Oelkers W; Berger V; Bolik A; Bähr V; Hazard B; Beier S; Elger W; Heithecker A
J Clin Endocrinol Metab; 1991 Oct; 73(4):837-42. PubMed ID: 1890155
[TBL] [Abstract][Full Text] [Related]
16. Drospirenone and its antialdosterone properties.
Genazzani AR; Mannella P; Simoncini T
Climacteric; 2007 Feb; 10 Suppl 1():11-8. PubMed ID: 17364593
[TBL] [Abstract][Full Text] [Related]
17. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
[TBL] [Abstract][Full Text] [Related]
18. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure.
Oelkers WK
Steroids; 1996 Apr; 61(4):166-71. PubMed ID: 8732994
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
De Leo V; Morgante G; Piomboni P; Musacchio MC; Petraglia F; Cianci A
Fertil Steril; 2007 Jul; 88(1):113-7. PubMed ID: 17418832
[TBL] [Abstract][Full Text] [Related]
20. Progestogens with antimineralocorticoid activity.
Losert W; Casals-Stenzel J; Buse M
Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
